Our most requested biosimilars and pharmaceutical products available for technology transfer
Once-weekly GLP-1 receptor agonist for type 2 diabetes and weight management. Complete tech transfer package available.
Dual GIP/GLP-1 receptor agonist. Next-generation diabetes and obesity treatment with enhanced efficacy.
TNF-alpha inhibitor biosimilar for rheumatoid arthritis, Crohn's disease, and inflammatory conditions.
Chemotherapy drug for breast, ovarian, and lung cancers. GMP-certified manufacturing available.
Anti-VEGF biosimilar for age-related macular degeneration and diabetic retinopathy treatment.
Platinum-based chemotherapy for ovarian, lung, and head/neck cancers. FDA/EMA compliant.
Unlimited CTD regulatory templates, expert pharmaceutical advisory, and AI-powered compliance monitoring. Accelerate your drug development timeline.
GMP-certified facilities delivering biosimilars, oncology injectables, and pharmaceutical excellence since 2005
Master formulas in 2–21 business days via secure portal. AI-accelerated development with complete documentation packages.
State-of-the-art facilities for biosimilars and oncology injectables. FDA/EMA/Health Canada/TGA/PMDA certified operations.
Comprehensive testing, method development, and ICH-compliant stability studies. Complete analytical support.
Contact our team to discuss your product requirements. We respond within 24 hours.